연구동향 분석

Changes in the Mean Corpuscular Volume after Capecitabine Treatment are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer

정현애 김현준 맹치훈 박세훈 이지연 박준오 박영석 임호영 강원기 2015년

논문상세정보
인용/피인용
' Changes in the Mean Corpuscular Volume after Capecitabine Treatment are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 내과학
  • capecitabine
  • macrocytosis
  • stomach neoplasms
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,578 0

0.0%

' Changes in the Mean Corpuscular Volume after Capecitabine Treatment are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer' 의 참고문헌

  • Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers
    Sun JF Gastrointest Cancer Res 3 : 134 ~ 140 [2009]
  • Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers
    Sun JF Gastrointest Cancer Res 3 134-140 [2009]
  • Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer
    van Triest B Clin Cancer Res 6 : 1063 ~ 1072 [2000]
  • Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer
    van Triest B Clin Cancer Res 6 1063-1072 [2000]
  • Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin : a randomised crossover trial in advanced colorectal cancer
    Borner MM Eur J Cancer 38 : 349 ~ 358 [2002]
  • Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin : a randomised crossover trial in advanced colorectal cancer
    Borner MM Eur J Cancer 38 349-358 [2002]
  • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    Therasse P J Natl Cancer Inst 92 205-216 [2000]
  • New guidelines to evaluate the response to treatment in solid tumors : European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    Therasse P J Natl Cancer Inst 92 : 205 ~ 216 [2000]
  • Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer
    Allegra CJ J Clin Oncol 20 : 1735 ~ 1743 [2002]
  • Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer
    Allegra CJ J Clin Oncol 20 1735-1743 [2002]
  • Effect of capecitabine on mean corpuscular volume of red blood cells
    Vrecl R Am J Clin Oncol 28 : 534 ~ [2005]
  • Effect of capecitabine on mean corpuscular volume of red blood cells
    Vrecl R Am J Clin Oncol 28 534- [2005]
  • Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer
    Karvellas CJ Am J Clin Oncol 27 : 364 ~ 368 [2004]
  • Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer
    Karvellas CJ Am J Clin Oncol 27 364-368 [2004]
  • Drug-induced megaloblastic change
    Scott JM Clin Haematol 9 : 587 ~ 606 [1980]
  • Drug-induced megaloblastic change
    Scott JM Clin Haematol 9 587-606 [1980]
  • Capecitabine: have we got the dose right?
    Midgley R Nat Clin Pract Oncol 6 : 17 ~ 24 [2009]
  • Capecitabine: have we got the dose right?
    Midgley R Nat Clin Pract Oncol 6 17-24 [2009]
  • Capecitabine treatment results in increased mean corpuscular volume of red blood cells in patients with advanced solid malignancies
    Wenzel C Anticancer Drugs 14 : 119 ~ 123 [2003]
  • Capecitabine treatment results in increased mean corpuscular volume of red blood cells in patients with advanced solid malignancies
    Wenzel C Anticancer Drugs 14 119-123 [2003]
  • Capecitabine in gastric cancer
    Okines A Drugs Today(Barc) 44 : 629 ~ 640 [2008]
  • Capecitabine in gastric cancer
    Okines A Drugs Today(Barc) 44 629-640 [2008]
  • Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?
    Twelves C. Oncology (Williston Park) 16 (12 Suppl No. 14) : 23 ~ 26 [2002]
  • Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?
    Twelves C. Oncology (Williston Park) 16 12 Suppl No. 14 23-26 [2002]
  • Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer
    Park SH Cancer Chemother Pharmacol 57 : 91 ~ 96 [2006]
  • Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer
    Park SH Cancer Chemother Pharmacol 57 91-96 [2006]
  • A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine(ECX)or cisplatin and capecitabine(CX)in advanced gastric cancer
    Yun J Eur J Cancer 46 : 885 ~ 891 [2010]
  • A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine(ECX)or cisplatin and capecitabine(CX)in advanced gastric cancer
    Yun J Eur J Cancer 46 885-891 [2010]